Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 36653904)

  • 1. Genetic alterations of GI-NECs involving three main signaling pathways.
    Dai Q; Zhang J; Long W; Haybaeck J; Yang Z
    Cancer Med; 2023 Apr; 12(7):8238-8250. PubMed ID: 36653904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NET G3 vs NEC: p53 and Rb1 Immunolabeling in High-grade Gastrointestinal Neuroendocrine Neoplasms - Is It Enough for the Differential Diagnosis?
    Dinu A; Aschie M; Cozaru GC; Mitroi AF; Grasa CN; Iordache IE; Deacu M; Orasanu CI; Nicolau AA; Baltatescu GI
    J Gastrointestin Liver Dis; 2023 Jun; 32(2):162-169. PubMed ID: 37345605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic characterization reveals distinct mutation landscapes and therapeutic implications in neuroendocrine carcinomas of the gastrointestinal tract.
    Wu H; Yu Z; Liu Y; Guo L; Teng L; Guo L; Liang L; Wang J; Gao J; Li R; Yang L; Nie X; Su D; Liang Z
    Cancer Commun (Lond); 2022 Dec; 42(12):1367-1386. PubMed ID: 36264285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin.
    Busico A; Maisonneuve P; Prinzi N; Pusceddu S; Centonze G; Garzone G; Pellegrinelli A; Giacomelli L; Mangogna A; Paolino C; Belfiore A; Kankava K; Perrone F; Tamborini E; Pruneri G; Fazio N; Milione M
    Neuroendocrinology; 2020; 110(7-8):616-629. PubMed ID: 31557757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular typing and mutational characterization of rectal neuroendocrine neoplasms.
    Duan X; Zhao M; Yin X; Mi L; Shi J; Li N; Han X; Han G; Wang J; Hou J; Yin F
    Cancer Med; 2023 Aug; 12(15):16207-16220. PubMed ID: 37387515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Mutational, Prognostic, and Therapeutic Landscape of Neuroendocrine Neoplasms.
    Liu M; Li N; Tang H; Chen L; Liu X; Wang Y; Lin Y; Luo Y; Wei S; Wen W; Chen M; Wang J; Zhang N; Chen J
    Oncologist; 2023 Sep; 28(9):e723-e736. PubMed ID: 37086484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours.
    Scarpa A
    Ann Endocrinol (Paris); 2019 Jun; 80(3):153-158. PubMed ID: 31072588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Metastatic Patterns Among Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Nonneuroendocrine Carcinomas of Various Primary Organs.
    Park HK; Kwon GY
    J Korean Med Sci; 2023 Mar; 38(11):e85. PubMed ID: 36942393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of ODF1 in Gastrointestinal Tract Neuroendocrine Neoplasms: a Novel Potential Immunohistochemical Biomarker for Well-differentiated Neuroendocrine Tumors.
    Li B; Li X; Mao R; Liu M; Fu L; Shi L; Zhao S; Fu M
    Endocr Pathol; 2021 Jun; 32(2):301-308. PubMed ID: 32869188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and prevalence of neuroendocrine neoplasms in Norway 1993-2021.
    Thiis-Evensen E; Boyar Cetinkaya R
    J Neuroendocrinol; 2023 Apr; 35(4):e13264. PubMed ID: 36988112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive genetic features of gastric mixed adenoneuroendocrine carcinomas and pure neuroendocrine carcinomas.
    Koh J; Nam SK; Kwak Y; Kim G; Kim KK; Lee BC; Ahn SH; Park DJ; Kim HH; Park KU; Kim WH; Lee HS
    J Pathol; 2021 Jan; 253(1):94-105. PubMed ID: 32985687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SATB2 in neuroendocrine neoplasms: strong expression is restricted to well-differentiated tumours of lower gastrointestinal tract origin and is most frequent in Merkel cell carcinoma among poorly differentiated carcinomas.
    Bellizzi AM
    Histopathology; 2020 Jan; 76(2):251-264. PubMed ID: 31233624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
    Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
    Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive Genomic Profiling of Neuroendocrine Carcinomas of the Gastrointestinal System.
    Yachida S; Totoki Y; Noë M; Nakatani Y; Horie M; Kawasaki K; Nakamura H; Saito-Adachi M; Suzuki M; Takai E; Hama N; Higuchi R; Hirono S; Shiba S; Kato M; Furukawa E; Arai Y; Rokutan H; Hashimoto T; Mitsunaga S; Kanda M; Tanaka H; Takata S; Shimomura A; Oshima M; Hackeng WM; Okumura T; Okano K; Yamamoto M; Yamaue H; Morizane C; Arihiro K; Furukawa T; Sato T; Kiyono T; Brosens LAA; Wood LD; Hruban RH; Shibata T
    Cancer Discov; 2022 Mar; 12(3):692-711. PubMed ID: 34880079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homogeneous MMR Deficiency Throughout the Entire Tumor Mass Occurs in a Subset of Colorectal Neuroendocrine Carcinomas.
    Fraune C; Simon R; Hube-Magg C; Makrypidi-Fraune G; Kluth M; Büscheck F; Amin T; Viol F; Fehrle W; Dum D; Höflmayer D; Burandt E; Clauditz TS; Perez D; Izbicki J; Wilczak W; Sauter G; Steurer S; Schrader J
    Endocr Pathol; 2020 Jun; 31(2):182-189. PubMed ID: 32144630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retinoblastoma co-repressor 1 (RB) and cyclin-dependent kinase inhibitor (CDKN) as a multi-gene panel for differentiating pulmonary from non-pulmonary origin in metastatic neuroendocrine carcinomas.
    Krishnamurthy K; Cusnir M; Schwartz M; Sriganeshan V; Poppiti RJ
    Pathol Res Pract; 2020 Sep; 216(9):153051. PubMed ID: 32825935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiological analysis of lung and mediastinal neuroendocrine neoplasms in Japan based on the national database.
    Matsuoka S; Koizumi T; Otsuki K; Tanaka Y; Kanda S; Ide S; Mishima S; Takeda T; Miura K; Eguchi T; Hamanaka K; Shimizu K
    Cancer Epidemiol; 2022 Apr; 77():102116. PubMed ID: 35144127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unraveling molecular pathways of poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: A systematic review.
    Girardi DM; Silva ACB; Rêgo JFM; Coudry RA; Riechelmann RP
    Cancer Treat Rev; 2017 May; 56():28-35. PubMed ID: 28456055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive analysis of mutational and clinicopathologic characteristics of poorly differentiated colorectal neuroendocrine carcinomas.
    Lee SM; Sung CO
    Sci Rep; 2021 Mar; 11(1):6203. PubMed ID: 33737597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 expression, tumor-infiltrating lymphocytes, and mismatch repair proteins status in digestive neuroendocrine neoplasms: exploring their potential role as theragnostic and prognostic biomarkers.
    Multone E; La Rosa S; Sempoux C; Uccella S
    Virchows Arch; 2024 May; ():. PubMed ID: 38771338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.